medigraphic.com
ISSN 0016-3813 (Print)

2003, Number 2

<< Back Next >>

Gac Med Mex 2003; 139 (2)

Molecular Aspects of Chronic Myeloid Leukemia

I. Introduction. Rafael Hurtado-Monroy
II. Development of Molecular Resistance to Imatinib.
III. Results with Imatinib in Accelerated- and Blastic-Phase Chronic Myeloid Leukemia (CML).
IV. Cyto

Hurtado-Monroy R, Cervera-Ceballos EE, Vargas-Viveros P, Cortes J

Language: Spanish
References: 61
Page: 119-130
PDF size: 118.42 Kb.


Text Extraction

No abstract


REFERENCES

  1. Vardiman JW, Imbert M, Pierre R, et al. Chronic myelogenous leucemia, in Jaffe ES, Harris NL, Hastíen H, et al (eds): Tumors of Haematopoietic and Lymphoid Tisues. World Health Organisation Classification of tumors. Lyon, France, AIRC Press 2001, p20-26.

  2. Kantarjian HM, Faderl S, Talpaz M. Chronic Myelogenous Leukemia, in De Vita VT Jr, Hellman S Rosenmerg SA (eds): Cancer Principles and Practice of Oncology (eds), Philadelphia, PA, Lippincot, Williams and Wilkins, 2001, pp 2433-2465.

  3. Barnes DJ, Melo JV. Management of Chronic Myeloid Leukemia: Targets for molecular Therapy. Semin Hematol 40:34-49;2003.

  4. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645-52.

  5. Druker BJ, Talpaz M, Resta D, et al. Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.

  6. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.

  7. O‘Dwyer ME, Mauro MJ, Kurilik G, et al. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 2002;100:1628-33.

  8. Gambacorti-Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. The Lancet Oncol 2003;4:75-85.

  9. Schindler T, Bornmann W, Pellicena P, et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000;289:1938-42.

  10. Sawyers C. Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Semin Hematol 2001;38(suppl 8):15-21.

  11. Goldman J. Implications of imatinib mesylate for hematopoietic stem cell transplantation. Semin Hematol 2001;38(suppl 38):28-34.

  12. Gambacorti-Passerini C, Zucchetti M, Russo D, et al. Alpha 1 acid glycoprotein (AGP) binds to STI571 and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003;9: in press.

  13. Sawyers Cl. Research on resistance to cancer drug Gleevec. Science 2001;294:1834.

  14. Druker BJ, O’Brien SG, Cortes J, Radich J. Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program). 2002;111-35.

  15. Hoover RR, Mahon FX, Melo JV, Daley GQ. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 2002;100:1068-71.

  16. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.

  17. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-37.

  18. Druker BJ, O’Brien Sg, Cortes J, Radich J. Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program). 2002;111-35.

  19. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-39.

  20. O’Dwyer ME, Mauro MJ, Kurilik G, et al. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 2002;100:1628-33.

  21. Drucker BJ, Talpaz M, Resta DJ, et al. Efficacy and Safety of a specific inhibitor of the BCR/ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037;2001.

  22. O‘Dwyer ME, Mauro MJ, Kurilik G, et al. The impact of clonal evolution on response to Imatinib mesylate (STI571) in accelerated phase CML. Blood 100:1628-1633;2002.

  23. Majlis A, Smith TL, O‘Brien S, et al. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol. 1996;14:196-203.

  24. Cortés J, Talpaz M, O‘Brien S, et al. Suppression of cytogenetic clonal evolution with interferon alfa therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. J Clin Oncol. 1998;16:3279-3285.

  25. Gorre ME, Mansoor M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 2001;293:876-880.

  26. Marktel S, G. Khalid, V. de Melo, et al. Emergence of additional chromosomal abnormalities following treatment with STI571 (Imatinib mesylate) for Philadelphia positive chronic myeloid leukemia in chronic phase. British Journal of Hematology, 2002;117(Suppl. 1)abstract No. 35.

  27. Marktel S, Marin D, Foot N, et al. Chronic myeloid leukemia in chronic phase responding to Imatinib: The occurrence of additional cytogenetic abnormalities predicts disease progression. Blood 100: No. 11(Suppl 1)Abstract 3106.November 16, 2002.

  28. Eric J. Feldman, Vesna Najfeld, Michael W. Schuster, et al. The emergence of Philadelphia chromosome (Ph) negative, trisomy 8 positive cells in patients with chronic myelogenous leukemia (CML) treated with Imatinib mesylate: Clinical evidence for a multistep pathogenesis. Blood 100: No. 11 (Suppl 1) Abstract 2299. November 16, 2002.

  29. Jorge E. Cortés, Moshe Talpaz, Francis Giles, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on Imatinib mesylate therapy. Blood. First edition paper, prepublished online January 30, 2003; DOI 10.1182/blood-2002-09-2.

  30. Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Medi. 2001;134:573-586.

  31. Sacchi S, Kantarjian HM, O’Brien S, Cortes J, Rios MB, Giles FJ, Beran M, Koller CA, Keating MJ, Talpaz M. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 1999;86:2632-2641.

  32. Kantarjian HM, O’Brien SM, Keating M, Beran M, Estey E, Giralt S, Kornblau S, Rios MB, de Vos D, Talpaz M. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia. 1997;11:1617-1620.

  33. Issa JP, Garcia-Manero G, Mannari R, Thomas D, Giles F, Cortes J, Estey E, Kantarjian H. Minimal effective dose of the hypomethylating agent decitabine in hematopoietic malignancies. Blood. 2001;98:594a.

  34. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Medi. 1999;341:164-172.

  35. Beaupre DM, Kurzrock R. RAS and leukemia: from basic mechanisms to gene-directed therapy. J Clini Oncol. 1999;17:1071-1079.

  36. Rowinsky EK, Windle JJ, Von Hoff DD. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clini Oncol. 1999;17:3631-3652

  37. Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001;97:3361-3369.

  38. Kurzrock R, Sebti SM, Kantarjian HM, Wright J, Cortes JE, Thomas DA, Wilson E, Beran M, Koller CA, O’Brien S, Freireich EJ, Talpaz M. Phase I study of a farnesyl transferase inhibitor, R115777, in patients with myelodysplastic syndrome. Blood. 2001;98:623a.

  39. Kurzrock R, Cortes JE, Ryback ME, Thibault A, Faderl S, Estey E, Garcia-Manero G, Giles F, Thomas DA, O’Brien S, Talpaz M, Kantarjian HM. Phase II study of R115777, a farnesyltransferase inhibitor, in myelodysplastic syndrome. Blood. 2001;98:848a.

  40. Peters DG, Hoover RR, Gerlach MJ, Koh EY, Zhang H, Choe K, Kirschmeier P, Bishop WR, Daley GQ. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 2001;97:1404-1412.

  41. Reichert A, Heisterkamp N, Daley GQ, Groffen J. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood. 2001;97:1399-1403.

  42. Hoover RR, Mahon F-X, Melo JV, Daley GQ. Overcoming STI571 resistance with the farnesyltransferase inhibitor SCH66336. Blood. 2001;98:617a.

  43. Thomas D, Cortés J, O’Brien S, García-Manero G, Kurzrock R, Giles F, Faderl S, Thibault A, Ryback ME, Kantarjian HM. R115777, a farnesyl transferase inhibitor (FTI), has significant anti-leukemia activity in patients with chronic myeloid leukemia. Blood. 2001;98:727a.

  44. Forkner CE, Scott TFM. Arsenic as a therapeutic agent in chronic myelogenous leukemia. JAMA. 1931;97:3

  45. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP, Jr. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Medi. 1998;339:1341-1348.

  46. Rousselot P, Labaume S, Marolleau JP, Larghero J, Noguera MH, Brouet JC, Fermand JP. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res. 1999;59:1041-1048.

  47. Wang ZG, Rivi R, Delva L, Konig A, Scheinberg DA, Gambacorti-Passerini C, Gabrilove JL, Warrell RP, Jr., Pandolfi PP. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood. 1998;92:1497-1504.

  48. Perkins C, Kim CN, Fang G, Bhalla KN. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood. 2000;95:1014-1022.

  49. Puccetti E, Guller S, Orleth A, Bruggenolte N, Hoelzer D, Ottmann OG, Ruthardt M. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity. Cancer Res. 2000;60:3409-3413.

  50. La Rosee P, Johnson K, Moseson EM, O’Dwyer M, Druker BJ. Preclinical evaluation of the efficacy of STI571 in combination with a variety of novel anticancer agents. Blood. 2001;98:839a

  51. Porosnicu M, Nimmanapalli R, Nguyen D, Worthington E, Perkins C, Bhalla KN. Co-treatment with As2O3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. Leukemia. 2001;15:772-778.

  52. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Research. 1999;59:2615-2622.

  53. Rothwarf DM, Karin M. The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Science’s STKE (Electronic Resource): Signal transduction knowledge environment. 1999;1999:RE1.

  54. Hamdane M, David-Cordonnier MH, D’Halluin JC. Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB). Oncogene. 1997;15:2267-2275.

  55. Reuther JY, Reuther GW, Cortéz D, Pendergast AM, Baldwin AS, Jr. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. Genes Dev. 1998;12:968-981.

  56. Dou QP, McGuire TF, Peng Y, An B. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells. J Pharmacol Experi Ther. 1999;289:781-790.

  57. Gatto SR, Scappini B, Verstovsek S, Milella M, Onida F, Ball G, Kantarjian HM, Keating MJ, Cortes J, Beran M. In vitro effects of PS-341 alone and in combination with STI571 in BCR-ABL positive cell lines both sensitive and resistant to STI571. Blood. 2001;98:101a.

  58. Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O’Brien S, Keating M, Freireich E, Albitar M. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240-2245.

  59. Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Giles FJ, Rogers A, Albitar M. Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia. Blood. 2002;99:2265-2267.

  60. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Medi. 1996;2:1096-1103.

  61. Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res. 1999;5:2963-2970.




2020     |     www.medigraphic.com